Publikationen bis 2010
Schott M, Schatz D, Atkinson M, Krischer J, Mehta H, Vold B und Maclaren N: GAD65Autoantibodies Increase the Predictibility but not the Sensitivity of Islet Cell and Insulin Autoantibodies for Developing Insulin Dependent Diabetes Mellitus. J Autoimmun 1994, 7:865-872 7.231
Seissler J, Schott M, Steinbrenner H, Peterson P, Krohn KJE und Scherbaum WA: Autoantibodies to adrenal cytochrome P450 antigens in isolated Addison’s disease and autoimmune polyglandular syndrome type II. Exp Clin Endocr Diab 1999, 107:208-131.685
Seissler J, Schott M, Boms S, Wohlrab U, Ostendorf B, Morgenthaler NG und Scherbaum WA: Autoantibodies to tissue transglutaminase identify silent coeliac diesase in type 1 diabetes. Diabetologia 1999; 42:1440-41 6.551
Schott M, Seissler J, Feldkamp J, von Schilling C und Scherbaum WA: Dendritic cell immunotherapy induces antitumor response in parathyroid carcinoma and neuroendocrine pancreas carcinoma. Horm Metab Res 1999, 31:662-664 2.686
Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA und Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: Technical and clinical evaluation. Horm Metab Res 2000, 32:429-435 2.686
Schattenberg D, Schott M, Reindl G, Krueger T, Tschoepe D, Feldkamp J, Scherbaum WA und Seissler J: Response of human monocyte-derived dendritic cells to immunostimulatory DNA. Eur J Immunol 2000, 30:2824-31 5.179
Seissler J, Schott M, Morgenthaler NG und Scherbaum WA: Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2. Clin Exp Immunol 2000, 122:157-633.009
Seissler J, Wagner S, Schott M, Lettmann M, Feldkamp J, Scherbaum WA und Morgenthaler NG: Low frequency of autoantibodies to the human Na+/J-symporter (NIS) in patients with autoimmune thyroid disease. J Clin Endocr Metab 2000, 85:4630-46.202
Schott M, Scherbaum WA und Feldkamp J: Medikamentöse Therapie endokriner Karzinome. Teil 1: Schilddrüsenkarzinome, Nebennierenkarzinome und Nebenschilddrüsenkarzinome. Med Klinik 2000, 95:20-5 (Review)0.473
Schott M, Scherbaum WA und Feldkamp J: Medikamentöse Therapie endokriner Karzinome. Teil 2: Maligne Gastrinome, Insulinome, Glukagonome, Karzinoide und andere Tumoren. Med Klinik 2000, 95:81-4 (Review)0.473
Feldkamp J, Pascher E, Schott M, Seissler J, und Scherbaum WA: Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. J Clin Endocr Metab 2001, 86:4520-42536.202
Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA und Feldkamp J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocinol Metab 2001, 86:4965-9 6.202
Seissler J, Eikamp K, Schott M und Scherbaum WA: IA-2 Autoantibodies restricted to the IgG4 Subclass are Associated with Protection from Type 1 Diabetes. Horm Metab Res 2002, 34:186-1912.686
Schott, M, Feldkamp, J, Klucken, M, Kobbe, G, Scherbaum, WA. und Seissler J: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immun 2002, 51:663-6683.791
Wagner S, Aust G, Schott M, Scherbaum WA, Feldkamp J. und Seissler J: Regulation of Sodium-iodide-symporter gene expression in human thyrocytes measured by real-time polymerase chain reaction. Exp Clin Endocr Diab 2002, 110:398-4021.685
Willenberg HS, Mansman NG, Fritzen R, Schott M, Feldkamp J, Schulte HM, Scherbaum WA und Bornstein SR: The short synacthen test in the evaluation of adrenal masses in patients with malignancies. Endocr Res 2002, 28:793-70.765
Krüger T, Wohlrab U, Klucken M, Schott M und Seissler J: Autoantigen-specific protein of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cells. Diabetologia 2003, 46:1357-1365 6.551
Schott M und Seissler J: Dendritic cell vaccination: New hope for the treatment of metastasized endocrine malignancies. Trends Endocrin Met 2003, 14:156-162 (Review)6.562
Schott M, Reincke M, Ortmann D und Bornstein SR: Immunotherapy: New strategies for the treatment of adrenocortical carcinoma. Horm Metab Res2003, 35:451-453 (Review)2.686
Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Scherbaum WA und Seissler J: Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves’ disease. Horm Metab Res 2004, 36:92-962.686
Rohr U B, Rehfeld N, Pflugfelder L, Geddert H, Steidl U, Fenk R, Gräf T, Schott M, Thiele K P, Gabbert H E, Germing U, Kronenwett R und Haas R: Expression of tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004, 111:259-634.722
Schott M, Scherbaum WA und Seissler J: Dendritic cell immunotherapy in thyroid malignancies. Curr Drug Targets 2004, 4:245-51 (Review)3.932
Schott M und Scherbaum WA: Immunotherapy and gene therapy of thyroid cancer. Minerva Endocrinologica 2004; 29:175-87 (Review)2.686
Schott M, Minich WB, Willenberg H, Fritzen R, Papewalis C, Schinner S, Seissler J, Scherbaum WA und Morgenthaler NG: Relevance of TSH receptor stimulating and blocking autoantibodies measurement for the prediction of relapse in Graves’ disease. Horm Metab Res 2005, 37:741-42.686
Willenberg HS, Haase M, Papewalis C, Schott M, Scherbaum WA und Bornstein SR: Corticotropin-releasing hormone (CRH) receptor expression on normal and tumorous human adrenocortical cells. Neuroendocrinology 2005, 82:274-813.074
Schott M, Scherbaum WA und Morgenthaler NG: TSH-receptor autoantibodies in Graves’ disease: Recent developments in the diagnosis and therapy monitoring. Trends Endocrin Met 2005, 16:243-8 (Review)6.562
Papewalis C, Fassnacht M, Domberg J, Willenberg H, Schinner S, Bornstein SR, Scherbaum WA und Schott M: Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf) 2006, 65:215-22 3.201
Willenberg HS, Schott M, Saeger W, Tries A, Scherbaum WA und Bornstein SR: Expression of connexins in chromaffin cells of normal human adrenals, benign and malignant pheochromocytomas. Ann NY Acad Sci 2006, 1073:578-832.670
Schott M: Immunesurveillance by dendritic cells: Potential implication for immunotherapy of endocrine cancers. Endocr-Relat Cancer 2006, 13:779-95 (Review)4.282
Schott M, Seissler J und Scherbaum WA: Diagnostic testing for autoimmune thyroid diseases. J Lab Clin Med 2006, 34:254-7 (Review)2.062
Schott M und Scherbaum WA: Antikörper-Diagnostik bei autoimmunen Schilddrüsenerkrankungen. Dtsch Arztebl Int 2006, 103:3023-32 (Review)2.686
Schott M, Willenberg H, Jung M, Knoefel WT and Scherbaum WA: Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous sampling. Clin Endocrinol (Oxf) 2007, 66:405-93.201
Schott M, Eckstein A, Schinner S, Willenberg HS, Morgenthaler NG und Scherbaum WA: Improved prediction of relapse of Graves’ thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies. Horm Metab Res 2007, 39:56-612.686
Haase M, Schott M, Bornstein SR, Malendowicz LK, Scherbaum WA und Willenberg HA: CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J Endocrinol 2007, 192:459-65 2.860
Schinner S, Willenberg HS, Krause D, Schott M, Ehrhart-Bornstein M, Bornstein SR und Scherbaum WA: Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obesity 2007, 31:564-70 4.343
Wertenbruch T, Sagert C, Feldkamp J, Willenberg HS, Groeger C, Scherbaum WA und Schott M: Serum selenium levels in patients with remission and relapse of Graves’ disease. Med Chemistry 2007, 3: 281-4 0.5
Tran N, Koch A, Berkels R, Boehm O, Zacharowski PA, Baumgarten G, Knuefermann, Schott M, Kanczkowski W, Bornstein SR, Lightman SL und Zacharowski K: Toll-like receptor 9 expression in murine and human adrenal glands and possible implications during inflammation. J Clin Endocr Metab 2007, 92:2773-83 6.202
Korthals M, Safaian N, Maihöfer D, Lara M, Schott M, Papewalis C, Kronenwett R, Kobbe G, Haas R und Fenk R: Monocyte-derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 2007, 25:463.407
Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Roher HD und Knoefel WT: Long term clinical follow up in medullary thyroid carcinoma: A single institution’s experience over 20 years. Ann Surg 2007, 246:815-8217.900
Willenberg H, Bahlo M, Schott M, Wertenbruch T, Feldkamp J und Schrbaum WA: Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute woman. Steroids 2008, 73:41-6 2.905
Schinner S, Ülgen F, Papewalis C, Schott M, Woelk A, Vidal-Puig A und Scherbaum WA: Regulation of insulin secretion, glucokinase gene transcription and ß-cell proliferation by adipocyte-derived wnt-signaling molecules. Diabetologia 2008, 51:147-546.551
Jacobs B, Papewalis C, Wuttke M, Ullrich E, Fenk R, Willenberg HS, Schinner S, Cohnen M, Seissler J, Zacharowski K, Scherbaum WA und Schott M: IFNa skews Monocyte Differentiation into CD56+ expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol 2008, 180:1462-705.646
Jacobs B, Wuttke M, Papewalis C, Fenk R, Stüssgen C, Schinner S, Seissler J und Schott M: Characterization of monocyte-derived IFNalpha-generated dendritic cells. Horm Metab Res 2008, 40:117-212.686
Papewalis C, Wuttke M, Jacobs B, Willenberg HS, Fenke M, Seissler J, Scherbaum WA und Schott M: Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008, 40:108-162.686
Domberg J, Chao L, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC und Schott M: Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 2008, 40: 416-212.686
Papewalis C, Wuttke M, Seissler J, Meyer Y, Kessler C, Jacobs B, Ullrich E, Willenberg HS, Schinner S, Baehring T, Scherbaum WA und Schott M: Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008, 14: 4298-3056.747
Sell MA, Schott M, Tharandt L, Cissewski C, Scherbaum WA und Willenberg HS: Functional central hypothyroidism in the elderly. Aging Clin Exp Res 2008, 20: 207-210 1.255
Liu C, Hermsen D, Domberg J, Graeber C, Hautzel H, Duan Y, Xu XF, Liu CP, Nao XD, Cupisti K, Scherbaum WA und Schott M: Comparison of M22-based ELISA and Human-TSH-Receptor-based Luminiscence Assay for the Measurement of Thyrotropin Receptor Autoantibodies in Patients with Thyroid Diseases. Horm Metab Res 2008, 40: 479-483 2.686
Jacobs B, Wuttke M, Papewalis C, Seissler J und Schott M: Dendritic cell subtypes and in vitro generation of DCs. Horm Metab Res 2008, 40:99-107 (Review)2.686
Seissler J und Schott M: Generation of insulin-producing beta cells from stem cells – Perspectives for cell therapy in type 1 diabetes. Horm Metab Res2008, 40:155-61 (Review)2.686
Schott M: Advances in cellular therapies. Horm Metab Res 2008, 40:99-107 (Review)2.686
Schott M: Rolle der Antikörperbestimmung für die Diagnose und Therapieentschei-dungen bei bestehender Hyperthyreose. Med Welt 2008; 59: 431-434 (Review)2.686
Liu C, Scherbaum WA und Schott M: Chemokines and Autoimmune Thyroid Diseases. Horm Metab Res 2008, 40: 361-368 (Review)2.686
Papewalis C, Jacobs B, Wuttke M und Schott M: Cellular therapies in endocrine diseases. Exp Clin Endocr Diab 2008, 116 Suppl: S33-99 (Review)1.685
Schott M und Bornstein SR: Symposium on „Recent developments in endocrinology and diabetes” honoring Werner A. Scherbaum. Exp Clin Endocr Diab 2008, 116 Suppl: S1-S3 (Review)1.685
Lehwald N, Cupisti K, Willenberg HS, Schott M, Krausch M, Raffel A, Wolf A, Brinkmann K, Eisenberger CF, Knoefel WT. Standard-radical vs. function-preserving surgery of benign nodular goiter - a sonographic and biochemical 10 years-follow-up study. Langenbeck Arch Surg 2009, 394: 279-831.572
Wuttke M, Papewalis C, Meier Y, Kessler C, Jacobs B, Willenberg HS, Kouatchoua C, Seissler J, Baehring T, Scherbaum WA und Schott M: Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma. Endocrinology 2008, 149: 5627-56344.752
Brocker-Preuss M, Sheu SY, Worm K, Feldkamp J, Witte J, Scherbaum WA, Mann K, Schmid KW und Schott M: Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma and its possible clinical implication. Horm Metab Res 2008, 40: 685-6912.686
Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, Mao X, Yu K, Wu X, Schinner S, Papewalis C, Scherbaum WA und Liu C: Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008; 40: 801-805 2.686
WuX, Schott M *, Liu C, QianC, Mao X, Xu K, Jiang J, Xu Y, Shen M, Scherbaum WA und Liu C: Statins decrease the aberrant HLA-DR expression on thyrocytes from patients with Hashimoto’s thyroiditis. Horm Metab Res 2008 ,40:838-41 2.686
Willenberg HS, Ansurudeen I, Schebesta K, Haase M, Wess B, Schinner S, Schott M und Scherbaum WA: The endothelium secretes interleukin-6 (IL-6) and induces adrenal IL-6 generation that does not interfere with the effect of endothelial cells on aldosterone synthesis. Exp Clin Endocr Diab 2008, 116: S70-741.685
Schinner S, Kempf K, Overmann H, Willenberg HS, Schott M, Rose B, Scherbaum WA und Herder C: Association of Impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. Exp Clin Endocr Diab 2008, 116: S64-691.685
Hermsen D, Liu C, Domberg J, Graeber C, Feldkamp J, Duan y, Xu K, Liu C, Mao X, Scherbaum WA und Schott M: Comparison of a solid phase human versus porcine thyrotropin receptor-based immunoassay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Exp Clin Endocr Diab 2008, 116: S59-63 1.685
Willenberg HS, Kolentini C, Quinkler M, Cupisti K, Krausch M, Schott M und Scherbaum WA: The sodium to urinary sodium to (potassium × potassium) to urinary potassium (SUSPPUP) ratio in primary aldosteronism. Eur J Clin Invest 2009, 39:43-50 2.643
Eckstein AK, LöschC, Glowacka D, Schott M, Mann K, EsserJ und Morgenthaler NG: Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves’ ophthalmopathy. Brit J Ophthalmol 2009, 93:1052-6 2.917
Hermsen D, Broecker-Preuss M, Casati M, Camara Mas J, Eckstein A, Gassner D, Golla R, van Helden J, Inomata K, Jarausch J, Kratzsch J, Mann K, Miyazaki N, Navarro Moreno MA, Murakami T, Roth HJ, Stock W, Yoshimura Noh J, Scherbaum WA und Schott M: Technical Evaluation of the First Automated Assay for the Detection of TSH Receptor Autoantibodies. Clin Chim Acta 2009, 401:84-92.535
Rohrbeck A, Neukirchen J, Rosskopf M, Garcia-Pardillos G, Geddert H, Schwalen A, Gabbert HE, von Haeseler A, Pitschke G, Schott M, Kronenwett R, Haas R, Rohr U-P: Gene expression profiling for molecular discrimination and characterization of laser captured primary lung cancers. J Transl Med 2008, 7;6:69 3.407
Lachenmayer A, Lichtenauer UD, Cox T, Schott M, Malendowicz LK, Goretzki PE, Cupisti C, Scherbaum WA, Bornstein SR und Willenberg HS: Nestin as a valuable marker in the classification of adrenocortical tumors. Horm Metab Res 2009, 41:397-4012.686
Haase M, Ansurudeen I, Paramonova I, Schinner S, Schott M, Papewalis C, Krug A, Scherbaum WA und Willenberg HS: Evidence for the involvement of endothelial cell products in adrenal CITED2 expression. Cell Tissue Res 2009, 336:337-432.308
Gu J, Quan C, Tang W, Wu X, Liu C, Mao X, Xu K, Scherbaum WA, Schott M und Liu C: Polychlorinated Biphenyls affect thyroid function and induce autoimmunity in SD rats. Horm Metab Res 2009, 41:471-4 2.686
Papewalis C, Wuttke M, Jacobs B, Willenberg HS, Schinner S, Scherbaum WA und Schott M: Role of the novel mTOR inhibitor RAD001 (Everolimus) in anaplastic thyroid carcinoma Horm Metab Res 2009, 41:752-6 2.686
Menge T, Schloot NC, Schott M, Hemmer B, Wiendl H, Hartung H-P und Kieseier BC: Interferon beta treatment does not induce organ-specific autoantibodies in patients with multiple sclerosis. Neurology 2009, 73:900-2 8.712
Erlic Z, Rybicki L, Peczkowska M, Hohenberg W, Kann PH, Dralle H, Müssig K, Muresan M, Schäffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plöckinger U, Peterssen S, Zabolotny D, Januszwicz A, Walz M, Eng C, und Neumann HPH for the European-American Pheochromocytoma Study Group: Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clin Cancer Res. 2009, 15:6378-85 6.747
Schott M, Hermsen D, Broecker-Preuss M, Casati M, Camara Mas J, Eckstein A, Gassner D, Golla R, Graeber C, van Helden J, Inomata K, Jarausch J, Kratzsch J, Miyazaki N, Navarro Moreno MA, Murakami T, Roth HJ, Stock W, Yoshimura Noh J, Scherbaum WA und Mann K: Clinical Evaluation of the First Automated TSH Receptor Autoantibody Assay: an International Multicenter Trial. Clin Endocrinol 2009, 71:566-733.201
Lehwald N, Cupisti K, Willenberg HS, Schott M, Krausch M, Raffel A, Wolf A, Brinkmann K, Eisenberger CF und Knoefel WT. Standard-radical vs. function-preserving surgery of benign nodular goiter - a sonographic and biochemical 10 years-follow-up study. Langenbecks Arch Surg 2009, 394: 279-831.500
Wuttke M, Papewalis C, Jacobs B und Schott M: Identifying tumor antigens in endocrine malignancies. Trends Endocrin Met 2009, 20 3):122-9 (Review)6.562
Papewalis C, Kouatchoua C, Wuttke M, Jacobs B, Scherbaum WA und Schott M: Chromogranin A as potential tumour antigen in pheochromocytoma. Horm Metab Res 2009, 41(9):707-9 (Review)2.686
Eckstein A, Mann K, Kahaly G, Grußendorf M, Reiners C, Feldkamp J, Quadbeck B, Bockisch A und Schott M: Bedeutung der TSH-Rezeptor-Antikörper für die Diagnose des Morbus Basedow und die Prognoseabschätzung der Schilddrüsenüberfunktion und der endokrinen Orbitopathie - Stellungnahme der Sektion Schilddrüse der DGE. Med Klinik 2009, 104(5):343-8 (Review)0.473
Schinner S, Willenberg HS, Schott M und Scherbaum WA: Pathophysiological aspects of wnt-signalling in endocrine diseases. Eur J Endocrinol2009,160(5):731-7 (Review)3.539
Publikationen bis 2015
Erlic Z, Hoffmann MM, Peczkowska M, Harsch I, Schott M, Gabbert E, Valimäki M, Preuss SF, Hasse-Lazar K, Waligorski D, Franke G, Robledo M, Januszewicz A, Eng C and Neumann HPH: Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocr Metab. 2010, 95:308-136.202
Raffel A, Eisenberger CF, Cupisti K, Baldus SE, Topp SA, Schulte am Esch J, Peiper J, Schott M, Knoefel WT und Stoecklein NK: Increased EpCAM expression in malignant insulinoma: Potential clinical implication. Eur J Endocrinol. 2010, 162:391-8 3.539
Hermsen D, Eckstein A, Schinner S, Willenberg HS, Thiel A, Scherbaum WA, Schott M: Reproducibility of Elecsys(R) Anti-TSHR Test Results in a Lot-to-Lot Comparison. Horm Metab Res. 2010, 42:295-7 2.686
Willenberg HS, Späth M, Maser-Gluth C, Engers R, Anlauf M, Dekomien G, Schott M, Schinner S, Cupisti K, Scherbaum WA: Sporadic solitary aldosterone- and cortisol-cosecreting adenomas – endocrine function tests, histological and genetic findings in a subtype of primary aldosteronism.Hypertens Res. 2010, 33:467-72 2.426
Ulgen F, Herder C, Kühn MC, Willenberg HS, Schott M, Scherbaum WA, Schinner S: Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem. 2010, 116:57-622.686
Erlic Z, Ploeckinger U, Cascón A, Hoffmann MM, von Duecker L, Winter A, Kammel G, Bacher J, Sullivan M, Isermann B, Fischer L, Raffel A, Knoefel WT, Schott M, Baumann T, Schaefer O, Keck T, Baum RP, Milos I, Muresan M, Peczkowska M, Januszewicz A, Cupisti K, Tönjes A, Fasshauer M, Langrehr J, von Wussow P, Agaimy A, Schlimok G, Lamberts R, Wiech T, Schmid KW, Weber A, Nunez M, Robledo M, Eng C, Neumann HP: Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. Endocr Relat Cancer. 2010, 17:875-834.282
Ulgen F, Kühn MC, Cupisti K, Herder C, Willenberg HS, Schott M, Scherbaum WA, Schinner S: The CB-1 Receptor Antagonist Rimonabant Modulates the Interaction Between Adipocytes and Pancreatic Beta-Cells in Vitro. Exp Clin Endocrinol Diabetes. 2010, 119:41-6 1.685
Balaş M, Zosin I, Maser-Gluth C, Hermsen D, Cupisti K, Schott M, Schinner S, Knoefel WT, Scherbaum WA, Willenberg HS: Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism. Hypertens Res. 2010, 33:850-6 2.426
Paramonova I, Haase M, Mülders-Opgenoorth B, Ansurudeen-Rafi I, Bornstein SR, Papewalis C, Schinner S, Schott M, Scherbaum WA, Willenberg HS: The effects of the endothelium on adrenal steroidogenesis and growth are mainly mediated by proteins other than endothelin-1. Horm Metab Res.2010, 42:840-5 2.686
Zöphel K, Roggenbuck D, Wunderlich G, Schott M: Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays. Horm Metab Res. 2010, 42:900-2 2.686
Hautzel H, Pisar E, Yazdan-Doust N, Schott M, Beu M, Müller HW: Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. J Nucl Med. 2010, 51:1917-226.424
Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol. 2015 Jun;172(6):677-85.3.539
de Corbière P, Ritzel K, Cazabat L, Ropers J, Schott M, Libé R, Koschker AC … Quinkler M, Touraine P, Villares Fragoso MC, Bertherat J, Bertagna X, Fassnacht M, Raffin-Sanson ML. Preganancy in Women Previously Treated for an Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2015 Dec;100(12):4604-11.6.310
Zöphel K, Roggenbuck D, Schott M: Clinical review about TRAb assay's history. . 2010, 9:695-700 (Review)6.368
Eckstein A, Esser J, Mann K, Schott M: Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. Pediatr Endocrinol Rev. 2010, 7 Suppl 2:198-203 (Review)2.686
Jacobs B, Papewalis C, Ehlers M, Schott M: Endocrine organs under the control of the immune system: potential implications for cellular therapies. Horm Metab Res. 2010, 42:912-7 (Review)2.686
Papewalis C, Ehlers M, Schott M: Advances in cellular therapy for the treatment of thyroid cancer. J Oncol. 2010, 2010:179491 (Review)2.686
Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A … Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein. Frequency and clinical correlates of somatic ying yang 1 mutations in sporadic insulinomas. J Clin Endocrinol Metab. 2015 May;100(5):E776-826.310
Publikationen bis 2019
Publikationen seit 2016
Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Schernthaner G, Thivolet C, Seissler J, Leslie RD; Action LADA Group. Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11. Diabetes Care. 2016 Nov;39(11):1932-1939. 
Ehlers M, Jordan AL, Feldkamp J, Fritzen R, Quadbeck B, Haase M, Allelein S, Schmid C, Schott MAnti-Thyroperoxidase Antibody Levels >500 IU/ml Indicate a Moderately Increased Risk for Developing Hypothyroidism in Autoimmune Thyroiditis. Horm Metab Res. 2016 Sep;48(10): 623-629. 
Ehlers M, Kuebart A, Hautzel H, Enczmann J, Reis AC, Haase M, Allelein S, Dringenberg T, Schmid C, Schott MEpitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2017 Jul 1;102(7):2154-2161.
Schwafertz C, Schinner S, Kühn MC, Haase M, Asmus A, Mülders-Opgenoorth B, Ansurudeen I, Hornsby PJ, Morawietz H, Oetjen E, Schott M, Willenberg HS. Endothelial cells regulate β-catenin activity in adrenocortical cells via secretion of basic fibroblast growth factor. Mol Cell Endocrinol. 2017 Feb 5; 441:108-115. 
Allelein S, Ehlers M, Goretzki S, Hermsen D, Feldkamp J, Haase M, Dringenberg T, Schmid C, Hautzel H, Schott MClinical Evaluation of the First Automated Assay for the Detection of Stimulating TSH Receptor Autoantibodies. Horm Metab Res. 2016 Dec;48(12): 795-801. 
Allelein S, Kuebart A, Haase M, Dringenberg T, Schmid C, Schott M, Ehlers M. Measurement of TSH Receptor Epitope-Specific T Cells in Graves' Disease. Horm Metab Res. 2016 Dec;48(12): 862-864. (Letter)
Dringenberg T, Sorokina M, Ehlers M, Dekomien G, Haase M, Schulze E, Quinkler M, Rump LC, Schott M, Willenberg HS. Evaluation of a Recently Established Test for Familial Hyperaldosteronism Type 1. Horm Metab Res2016 Dec;48(12): 865-868. 
Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, Blaser R, Spitzweg C, Fassnacht M, Schott M, Führer D, Tiedje V. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016 Dec;175(6): 521-529.

Allelein S, Feldkamp J, Schott M. [Autoimmune diseases of the thyroid gland]. Internist (Berl). 2017 Jan;58(1):47-58. (Review)

Allelein S, Feldkamp J, Schott M. [Current Diagnostics and Treatment of Thyroid Nodules]. Dtsch Med Wochenschr. 2017 Aug;142(15):1097-1100. (Review)

Haase M, Dringenberg T, Allelein S, Willenberg HS, Schott M. Excessive Catecholamine Secretion and the Activation of the Renin-Angiotensin-Aldosterone-System in Patients with Pheochromocytoma: A Single Center Experience and Overview of the Literature. Horm Metab Res. 2017 Oct;49(10):748-754. (Review)

Werner TA, Dizdar L, Nolten I, Riemer JC, Mersch S, Schütte SC, Driemel C, Verde PE, Raba K, Topp SA, Schott M, Knoefel WT, Krieg A. Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma. Sci Rep. 2017 Sep 12;7(1):11383.
Werner TA, Forster CM, Dizdar L, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A. CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. Br J Cancer2017 Dec 5;117(12):1837-1845. 
Allelein S, Ehlers M, Morneau C, Schwartz K, Goretzki PE, Seppel T, Feldkamp J, Krieg A, Knoefel WT, Kuebart A, Haase M, Dringenberg T, Schmid C, Schott MMeasurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Horm Metab Res. 2018 Jan;50(1):23-28. 
Werner TA, Nolten I, Dizdar L, Riemer JC, Schütte SC, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A. IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer. Endocr Relat Cancer. 2018 Mar;25(3):295-308. 
Werner TA, Forster CM, Dizdar L, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A. CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma. J Cancer. 2018 Feb 27;9(6):929-940. 
Krauss T, Ferrara AM, Links TP, .... , Schott M, ... Neumann HPH, Bausch B. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018 Sep;25(9):783-793. 
Feldkamp J, Jungheim K, Schott M, Jacobs B, Roden M. Severe Vitamin D3 Deficiency in the Majority of Patients with Diabetic Foot Ulcers. Horm Metab Res. 2018 Aug;50(8):615-619. 
Ehlers M, Allelein S, Schwarz F, Hautzel H, Kuebart A, Schmidt M, Haase M, Dringenberg T, Schott MIncreased Numbers of Circulating Tumor Cells in Thyroid Cancer Patients. Horm Metab Res2018 Aug;50(8):602-608. 
Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. Int J Cancer. 2018 Aug 24.

AWMF-Empfehlungen [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol. 2018 Jun;56(6):583-681. (Review)

Banga JP, Schott M: Autoimmune Thyroid Disaeses. Horm Metab Res 2018 Dec;50(12):837-839 (Editorial)

Frank-Raue K, Schott M, Raue F; im Namen der Sektion Schilddrüse der DGE. [Recommendation for Calcitonin Screening in Nodular Goiter]. Dtsch Med Wochenschr. 2018 Aug;143(15):1065-1069. (Review)

Allelein S, Diana T, Ehlers M, Kanitz M, Hermsen D, Schott M, Kahaly GJ: Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation. Horm Metab Res 2019 Jun;51(6):341-346

Schott M, R Bornstein S, A Stratakis C: Hormone and Metabolic Research: 50 years of Research. Horm Metab Res 2019 Jan;51(1):8-10 (Editorial)

Allelein S, Schott M: Update Graves’ disease 2019. Dtsch Med Wochenschr. 2019 Feb;144(3):152-155 (Review)

Ehlers M, Schott M, Allelein S: Graves’ disease in clinical perspective. Front Biosci (Landmark Ed). 2019 Jan 1;24:35-47 (Review)

Publikationen seit 2020

Kratzsch J, Baumann NA, Ceriotti F, Lu ZX, Schott M, van Herwaarden AE, Henriques Vieira JG, Kasapic D, Giovanella L.: Global FT4 immunoassay standardization: an expert opinion review. Clin Chem Lab Med. 2020 Dec 24;59(6):1013-1023

Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knösel T, Sandner B, Fenske WK, Bläker H, Smaxwil C, Zielke A, Sipos B, Allelein S, Schott M, Dierks C, Spitzweg C, Fassnacht M, Kroiss M.: FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne). 2021 Aug 12;12: 712107

Koehler VF, Berg E, Adam P, Weber GL, Pfestroff A, Luster M, Kutsch JM, Lapa C, Sandner B, Rayas N, Fuss CT, Kreissl MC, Hoster E, Allelein S, Schott M, Todica A, Fassnacht M, Kroiss M und Spitzweg C: Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer. Thyroid 2021 Oct;31(10):1531-1541.

Schmidt M, Antke C, Mattes-György K, Hautzel H, Allelein S, Haase M, Dringenberg T, Schott M, Ehlers M.: Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2021 Jun;94(6):1004-1011

Allelein S und Schott M: Graves‘ Disease. Dtsch Med Wochenschr. 2021 Oct;146(20):1337-1343

Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch C, König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M.: Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: Expert Perspectives. Horm Metab Res. 2021 Mar;53(3):149-160

Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch C, König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M.: Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: Expert Perspectives. Horm Metab Res. 2021 Mar;53(3):149-160

Kratzsch J, Baumann NA, Ceriotti F, Lu ZX, Schott M, van Herwaarden AE, Henriques Vieira JG, Lehmann H, Kasapic D, Giovanella L.: The new Roche Elecsys TSH assay conforms withcurrent IFCC C-STFT standards Clin Chem Lab Med. 2021 Jul 13;59(12): e445-e448

Prassas D, Kounnamas A, Cupisti K, Schott M, Knoefel WT, Krieg A.: Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer: A Single Center Cohort Study. Ann Surg Oncol. 2022 Apr;29(4): 2561-2569

Ehlers M, Schmidt M, Mattes-Gyorgy K, Antke C, Enczmann J, Schlensog M, Japp A, Haase M, Allelein S, Dringenberg T, Giesel F, Esposito I, Schott M: BRAF V600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer. Horm Metab Res 2022 Dec; 54(12): 852-858

Koehler VF, Adam P, Fuss CT, Jian L, Berg E, Frank-Raue K, Raue F, Hoster E, Knösel T, Schildhaus HU, Negele T, Siebolts U, Lorenz K, Allelein S, Schott M, Spitzweg C, Kroiss M; German Study Group for Rare Malignant Tumors oft he Thyroid and Parathyroid Glands: Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors – A retrospective Multi-Center Registry Analysis. Cancers (Basel) 2022 Jul;13;14(14): 3405

Stylianidi MC, Haeberle L, Schott M, Mory Y, Antke C, Giesel FL, Antoch G, Esposito I, Knoefel WT, Krieg A: Primary thyroid gland myxofibrosarcoma: a case report and review of the literature. Surg Case Rep 2022 Jul 25;8(1): 139

Boschheidgen M, Kantauskaite M, Stegbauer J, Wenker K, Dringenberg T, Radke KL, Ullrich T, Krieg A, Steuwe A, Minko P, Schott M, Rump LC, Antoch G, Schimmöller L: Contrast medium free selective adrenal vein sampling in the management of primary aldosteronism. Clin Imaging 2023 Jul;99: 25-30

David SO, Krieg S, Esposito I, Schott M, Giesel FL, Roderburg C, Loosen SH, Luedde T, Knoefel WT, Krieg A: A Revised Version of the TNM Classification Leads to Optimized Predictive Performance in Patients with Adrenocortical Carcinoma. Horm Metab Res 2023 Apr; 55(4)227-235

MediathekInformation und Wissen
LageplanSo finden Sie uns